Melatonin as a Secondary Therapy for COVID-19


В. Й. Мамчур
Д. С. Носівець
О. В. Хом’як


The authors on the basis of analytical review of the world literature analyzed the pharmacological activity of melatonin in the aspect of clinical use in COVID-19. Melatonin is traditionally considered a hormone of the pineal gland, which provides the interaction of organism with environment for information about the light regime of the environment. Until recently, the main scope of this drug was various sleep disorders. However, subsequent studies revealed that the melatonin’s ability to exert anticonvulsant, antidepressant, antineoplastic, neuroprotective, antioxidant and anti-gonadotropic effect and have some therapeutic activity for pharmacotherapy of tinnitus, migraine, neurodegenerative diseases, epilepsy, breast cancer, diseases of the respiratory and cardiovascular systems.

The article found that a valuable effect of melatonin is its ability to reduce the release of proinflammatory cytokines, thereby reducing the intensity of inflammation and «cytokine storm» in patients with COVID-19.

The paper notes that melatonin’s role as antioxidant, reduce the risk of oxidative stress during inflammation, but also as a factor of prevention of the development of «cytokine storm», with the development of which is associated with high risks of mortality at COVID-19. Melatonin is effective in patients hospitalized with COVID-19 by reducing vascular permeability, levels of General anxiety, use of sedatives and improve sleep quality.

Found that melatonin can be used in combination with drugs and therapies COVID-19. For example, melatonin and alpha-lipoic acid may decrease kidney damage from oxidative stress caused by a combination of antiviral medications lopinavir/ritonavir. Using melatonin to mitigate medical and social problems in the context of a global pandemic may be substantial and socially responsible measure to preserve and maintain the health of the population.

The authors found that the pharmacological activity of melatonin in the aspect of clinical use in COVID-19 is associated with its antioxidant and anti-stress activity that can be used effectively in conditions of coronavirus infection.


How to Cite
Мамчур, В. Й., Носівець, Д. С., & Хом’як, О. В. (2020). Melatonin as a Secondary Therapy for COVID-19. Family Medicine, (3), 13–19.
Topical issues
Author Biographies

В. Й. Мамчур, State Establishment «Dnipropetrovsk Medical Academy of Health Ministry of Ukraine»

Vitalii Yo. Mamchur,

Department of Pharmacology and Clinical Pharmacology

Д. С. Носівець, State Establishment «Dnipropetrovsk Medical Academy of Health Ministry of Ukraine»

Dmytro S. Nosivets,

Department of Pharmacology and Clinical Pharmacology

О. В. Хом’як, State Establishment «Dnipropetrovsk Medical Academy of Health Ministry of Ukraine»

Olena V. Khomyak,

Department of Pharmacology and Clinical Pharmacology


Claustrat B., Leston J. Melatonin: Physiological effects in humans Neurochirurgie. 2015, 61, 2-3:77–84.

Мендель В.Э., Мендель О.И. Мелатонин: роль в организме и терапевтические возможности. Опыт применения препарата Мелаксен в российской медицинской практике. РМЖ. 2010, 6:336–345.

Amaral F.G., Cipolla-Neto J. A brief review about melatonin, a pineal hormone. Arch Endocrinol Metab. 2018, 62, 4:472–479.

Cipolla-Neto J., Amaral F.G. Melatonin as a Hormone: New Physiological and Clinical Insights. Endocrine Reviews. 2018, 39: 990–1028.

Reiter R.J., Rosales-Corral S.A., Tan D.X., Acuna-Castroviejo D., Qin L., Yang S.F., Xu K. Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis. Int. J. Mol. Sci. 2017, 18, 843; doi:10.3390/ijms18040843

Reiter R.J., Rosales-Corral S., Tan D.X., Jou M.J., Galano A., Xu B. Melatonin as a Mitochondria-Targeted Antioxidant: One of Evolution’s Best Ideas. Cell Mol Life Sci. 2017, 74, 21:3863–3881. doi: 10.1007/s00018-017-2609-7.

Suna H., Gusdonb A.M., Qu S. Effects of melatonin on cardiovascular diseases: progress in the past year. Curr Opin Lipidol. 2016, 27:408–413.

Habtemariam S., Daglia M., Sureda A., Selamoglu Z., Gulhan M.F., Nabavi S.M. Melatonin and Respiratory Diseases: A Review. Curr Top Med Chem. 2017;17(4):467–488. doi: 10.2174/1568026616666160824120338.

Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Временные методические рекомендации. Версия 5 (08.04.2020). Доступно –

Шипилов М.В. Молекулярные механизмы «цитокинового шторма» при острых инфекционных заболеваниях. Лечебное дело. 2013, 6:81–85.

Застосування ліків при COVID-19. Видання Державного Експертного Центру МОЗ України. Оновлено 22.05.2920. Доступно –

Sanders J.M., Monogue M.L., Jodlowski T.Z. et al. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19). JAMA. 2020;323(18):1824–1836. doi:10.1001/jama.2020.6019

Zhanga R., Wanga X., Nia L., Dia X., Maa B., Niua S., Liua C., Reiterb R.J. COVID-19: Melatonin as a potential adjuvant treatment. Life Sciences. 2020, 250:117–583.

Melatonin Inhibits COVID-19-induced Cytokine Storm by Reversing Aerobic Glycolysis in Immune Cells: A Mechanistic Analysis Medicine in Drug Discovery. 2020, 6:100–044.

Herrera E.A., Gonzalez-Candia A. Comment on Melatonin as a potential adjuvant treatment for COVID-19, Life Sciences. 2020,

Anderson G., Reiter R.J. Melatonin: Roles in influenza, Covid-19, and other viral infections. Rev Med Virol. 2020,30:21–09.

Margarita V., Giméneza M., Inserrab F., Tajerc C.D., Marianid J., Ferderb L., Reitere R.J., Manuchaf W. Lungs as target of COVID-19 infection: Protective common molecular mechanisms of vitamin D and melatonin as a new potential synergistic treatment. Life Sciences. 2020, 254:117–808.

Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol 2020. Published online April 10.

Wu GC, Peng CK, Liao WI, et al. Melatonin receptor agonist protects against acute lung injury induced by ventilator through up-regulation of IL-10 production. Respir Res 2020;21(1):65.

Salluh JI, Wang H, Schneider EB, et al. Outcome of delirium in critically ill patients: systematic review and metaanalysis. BMJ 2015,350:25–38.

Zhang Q, Gao F, Zhang S, et al. Prophylactic use of exogenous melatonin and melatonin receptor agonists to improve sleep and delirium in the intensive care units: a systematic review and meta-analysis of randomized controlled trials. Sleep Breath 2019;23(4):1059e70.

Справочник РЛС. Регистр лекарственных средств России. Доступно –

Справочник лекарственных средств Украины «Компендиум». Доступно –

Справочник лекарственных средств «Vidal». Доступно –